IDEXX Laboratories Q3 Revenue Rises 10%; Comparable EPS Reaches $3.96
IDEXX Laboratories reported Q3 2026 revenue of $1.214B, up 10% YoY, and diluted EPS of $4.01. Comparable EPS rose 22% to $3.96. The company raised its 2026 revenue and EPS forecasts but lowered its operating-margin outlook. Key growth areas included CAG Diagnostics and Water revenue.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive short‑term buying interest, while the margin downgrade may introduce caution among value‑focused investors.
Market read
Strong earnings and upward guidance make IDEXX a potential short‑term rally candidate within the animal health sector.
What to watch
Acquisition of CoVet may require integration spend, and slower assay volumes could impact near‑term profitability.
Background
IDEXX is a leading provider of veterinary diagnostics and software solutions, regularly reporting quarterly results.
Ticker impact
IDEXX Laboratories reported Q3 2026 results with revenue up 10% YoY and raised full-year guidance.
potential upside as market prices in higher revenue and EPS outlook
Revenue and EPS guidance were increased, while operating margin outlook was modestly lowered, indicating growth expectations outweigh margin concerns.
Market effects
Positive for veterinary diagnostics and animal health sector as IDEXX leads with new AI assistant acquisition.
U.S. healthcare and biotech equities may see modest lift.
Limited to investors tracking animal health and diagnostic equipment markets.
Counterpoint
Margin guidance was lowered, which could temper enthusiasm if cost pressures persist.
Key entities
- companyIDEXX Laboratories
Veterinary diagnostics and software provider
- companyCoVet
AI clinical assistant acquired by IDEXX
